COMBINING GERMLINE AND SOMATIC TESTING EMPOWERS YOU TO NAVIGATE COMPLEX DECISIONS IN ADVANCED PROSTATE CANCER CARE.

MyRisk® Hereditary Cancer Test

Precise Tumor™ Molecular Profile Test

Combining germline and somatic testing reveals more.

1 in 4
men with advanced prostate cancer have actionable tumor changes that may inform treatment decisions.[1,2]

1 in 6
men with advanced prostate cancer have a clinically actionable germline variant.[3,4]

1 in 10
germline variants are missed through tumor testing alone.[3,5]

Men with advanced prostate cancer may qualify for targeted treatments based on their germline and somatic mutation status[6]

Men with germline mutations in genes such as *BRCA1* and *BRCA2* are more prone to developing aggressive prostate cancer and have higher rates of nodal involvement and distant metastasis.[7]

Patients with localized prostate cancer and *BRCA* mutation are:[4]

6x
more likely to die from prostate cancer within 5 years

4x
more likely to develop metastasis within 5 years

At the same time, patients with *BRCA1* or *BRCA2* mutations may respond better to DNA-damaging therapies, including PARP inhibitors—potentially reducing their risk of disease progression or death.[5,6,8]

Genetic testing is essential to identify patients more likely to develop aggressive disease—and those who may benefit from targeted therapies such as PARP inhibitors.[6,7]

Myriad Oncology™

Clinical guidelines support combined testing for patients with prostate cancer

National Comprehensive Cancer Network (NCCN) guidelines recommend:[6]

Germline testing

for all patients with high-risk, very high-risk, regional, or metastatic prostate cancer (or any stage with family history suggestive of hereditary cancer).

+

Somatic tumor testing

for metastatic prostate cancer to detect DNA repair gene mutations (e.g., *BRCA1, BRCA2, ATM,* etc.) relevant for PARP inhibitor eligibility and other targeted therapies.

Combining germline and somatic testing doubles the chances of identifying clinically actionable mutations

Tumor-specific

(somatic) alterations—including mutations in HRR genes such as *BRCA1, BRCA2,* and *ATM*—can only be identified through somatic testing.

Up to 10%

of *BRCA* mutations are large rearrangements, which tumor testing alone misses.[9]

2x

the chance of identifying clinically actionable mutations when combining germline and somatic testing.[3]

Myriad Oncology™ offers genomic clarity for high-risk, progressive prostate cancer

Patients with metastatic castration-resistant prostate cancer (mCRPC) experience high rates of somatic and germline mutations.[1-4]

Myriad's industry-leading variant classification qualifies more patients for targeted therapies and clinical trials.[10]

PARP inhibitor therapy may cut the risk of disease progression or death in patients with prostate cancer and a g*BRCA* mutation.[2]

Combined testing with Myriad Oncology™

By ordering both the MyRisk® Hereditary Cancer Test and the Precise Tumor® Molecular Profile Test from Myriad Oncology, you get consolidated, concordant results—avoiding the inconsistencies that arise when multiple labs interpret variants differently. Our integrated approach means clearer reporting, fewer redundancies, and greater confidence in distinguishing inherited from somatic mutations, helping you identify more patients for targeted therapies and clinical trials.

MyRisk®
Hereditary Cancer Test

Performed on blood or saliva sample

The MyRisk test is a guideline-driven germline test that evaluates clinically actionable genes to help healthcare providers personalize care plans.

- Detects germline *BRCA1* and *BRCA2* pathogenic variants that may influence the use of targeted therapies such as PARP inhibitors[6]
- Delivers the industry's lowest reported VUS rate for *BRCA1* and *BRCA2* of 0.3% and 0.7%, respectively[11]
- Identifies hereditary cancer syndromes, providing information to facilitate family risk assessment[12]

Precise Tumor™
Molecular Profile Test

Performed on tissue sample

Precise Tumor is a somatic test that analyzes over 500 genes, as well as key biomarkers, with broad coverage of guidelines.[13]

- Determines eligibility for FDA-approved therapies and clinical trials
- Includes DNA, RNA, and immuno-oncology biomarkers such as MSI, TMB, and PD-L1 for more actionable findings
- Combines DNA and RNA sequencing to detect more fusions and splice variants compared to DNA-only tests[14-17]

The Precise Tumor test detects key guideline biomarkers for multiple cancer types, plus current and emerging pan-cancer biomarkers, including:

Breast	Ovarian	Endometrial	Colon	Pancreatic	Prostate	Lung	Pan-Cancer
AR *BRCA1* *BRCA2* *ERBB2 (HER2)* *ESR1* *PD-L1* *PGR* *PIK3CA* *PTEN*	*BRAF* *BRCA1* *BRCA2* *MLH1* *MSH2* *MSH6* *PMS2*	*ERBB2* *ESR1* *MLH1* *MSH2* *MSH6* *PMS2* *POLE* *TP53*	*BRAF* *ERBB2* *KRAS* *NRAS* *MLH1* *MSH2* *MSH6* *PMS2*	*ALK* *BRAF* *BRCA1* *BRCA2* *ERBB2* *FGFR2* *KRAS* *NRG1* *PALB2* *RET* *ROS1*	*ATM* *AR* *BRCA1* *BRCA2* *CDK12* *CHEK2* *FANCA* *MLH1* *MSH2* *MSH6* *PALB2* *PMS2* *RAD51D*	*ATK1* *ALK* *BRAF* *DDR2* *EGFR* *ERBB2* *FGFR1* *FGFR2* *FGFR3* *KRAS* *MAP2K1* *MET* *NRAS* *PIK3CA* *PTEN* *RET* *TP53* *PD-L1*	*NTRK1* *NTRK2* *NTRK3* *TMB*

The Precise Tumor test is validated to 98.91% analytical sensitivity and >99.99% analytical specificity[13]

More answers for your patients with industry-leading variant classification

Myriad leads the industry in detecting and classifying known germline variants, including when other labs return a variant of uncertain significance (VUS) result—providing more actionable answers for more patients.



of VUS from other labs were definitively classified by the MyRisk test.[10]

VUS rate for ***BRCA1***	VUS rate for ***BRCA2***
0.3%	**0.7%**

The MyRisk test delivers the industry's lowest reported VUS rate for *BRCA1* and *BRCA2*.[11]

Myriad Oncology provides combined germline and somatic testing and extensive support services — empowering you to confidently guide every step of the cancer journey

Myriad streamlines your workflow with comprehensive services, including EMR integration

Treatment-focused reporting includes an actionable, single-sheet summary

Consolidated germline and tumor genomic results are typically available within 14 days

Myriad's Patient Education Program includes pre- and post-test education by board-certified genetic counselors

LEARN MORE
myriad.com/oncology

Germline

MyRisk®
Hereditary Cancer Test

Tumor Genomic

Precise Tumor™
Molecular Profile Test

Prolaris®
Prostate Cancer Prognostic Test

MyChoice® CDx
Myriad HRD Companion Diagnostic Test

EndoPredict®
Breast Cancer Prognostic Test

References: 1. Robinson D, Van Allen EM, Wu YM, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015;161(5):1215-1228. **2.** de Bono J, Mateo J, Fizazi K, et al. Olaparib for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2020;382(22):2091-2102. **3.** Berchuck JE, Boiarsky D, Silver R, et al. Addition of Germline Testing to Tumor-Only Sequencing Improves Detection of Pathogenic Germline Variants in Men With Advanced Prostate Cancer. JCO Precis Oncol. 2022;6:e2200329. **4.** Nicolosi P, Ledet E, Yang S, et al. Prevalence of Germline Variants in Prostate Cancer and Implications for Current Genetic Testing Guidelines. JAMA Oncol. 2019;5(4):523-528. **5.** Tung N, Ricker C, Messersmith H, et al. Selection of Germline Genetic Testing Panels in Patients With Cancer: ASCO Guideline. J Clin Oncol. 2024;42(21):2599-2615. **6.** Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer, Version 2.2025 — April 16, 2025. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. To view the most recent and complete version of the guideline, visit NCCN.org. **7.** Castro E, Goh C, Olmos D, et al. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol. 2013;31(14):1748-1757. **8.** Lee JM, Ledermann JA, Kohn EC. PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies. Ann Oncol. 2014;25(1):32-40. **9.** Judkins T, Rosenthal E, Arnell C, et al. Clinical significance of large rearrangements in *BRCA1* and *BRCA2*. Cancer. 2012;118(21):5210-5216. **10.** Gradishar W, Johnson K, Brown K, Mundt E, Manley S. Clinical Variant Classification: A Comparison of Public Databases and a Commercial Testing Laboratory. Oncologist. 2017;22(7):797-803. **11.** Mundt E, McGreevy K, Nix P, Cummings S. Myriad's Multidisciplinary Approach and Consistent Investment in Variant Classification for Clinical Decision Making [White paper]. Myriad Genetics. 2025. **12.** National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Genetic /Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic. Version 3.2024. 2024 February 12; National Comprehensive Cancer Network. Available from: https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf. **13.** Conroy JM, Pabla S, Glenn ST, et al. A scalable high-throughput targeted next-generation sequencing assay for comprehensive genomic profiling of solid tumors. PLoS One. 2021;16(12):e0260089. **14.** Benayed R, Offin M, Mullaney K, et al. High yield of RNA sequencing for targetable kinase fusions in lung adenocarcinomas with no mitogenic driver alteration as detected by DNA sequencing and low tumor mutation burden. Clin Cancer Res. 2019;25(15):4712-4722. **15.** Wong W, Butaney M, Schneider J, et al. Methods for identifying patients with tropomyosin receptor kinase (TRK) fusions. Pathol Oncol Res. 2020;26(3):1385-1399. **16.** Yang Y, Qin G, Li Y, et al. A performance comparison of commonly used assays to detect RET fusions. Clin Cancer Res. 2020;26(24):6547-6556. **17.** Radonic T, Geurts-Giele WRR, Samsom KG, et al. RET FISH analysis is a sensitive but highly unspecific method for RET fusions in lung cancer. J Thorac Oncol. 2021;16(2):258-265.

Myriad Oncology™